Pichler and colleagues (2018) (16) analyzed the 5-mRNA (ABL1, ANXA10, UPK1B, CRH, and IGF2) model proposed by Wallace and colleagues (2018) (17), now named Xpert BC Monitor and showed that it presents sensitivity superior to cytology, even in NMIBC low-grade and pTa disease, while overall specificity is similar. The gene discussed is ANXA10; the disease is breast cancer.